- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Pricing and reimbursement of orphan drugs: the need for more transparency ; volume:6 ; number:1 ; day:17 ; month:6 ; year:2011 ; pages:1-8 ; date:12.2011
Orphanet journal of rare diseases ; 6, Heft 1 (17.6.2011), 1-8, 12.2011
- Urheber
-
Simoens, Steven
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1750-1172-6-42
- URN
-
urn:nbn:de:1111-2016050120203
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Simoens, Steven
- SpringerLink (Online service)
Ähnliche Objekte (12)
Reimbursement of orphan drugs in Belgium: what (else) matters?
A systematic review of moral reasons on orphan drug reimbursement
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
Drug pricing and reimbursement decision making systems in Mongolia
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Complex pricing and consumer-side transparency
Variables affecting pricing of orphan drugs: the Italian case
Pricing and Reimbursement of Prescription Drugs in German Social Health Insurance
On the welfare analysis of external reference pricing and reimbursement policy
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
Reimbursement of orphan drugs in Belgium: what (else) matters?
A systematic review of moral reasons on orphan drug reimbursement
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
Drug pricing and reimbursement decision making systems in Mongolia
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Complex pricing and consumer-side transparency
Variables affecting pricing of orphan drugs: the Italian case
Pricing and Reimbursement of Prescription Drugs in German Social Health Insurance
On the welfare analysis of external reference pricing and reimbursement policy
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
Reimbursement of orphan drugs in Belgium: what (else) matters?
A systematic review of moral reasons on orphan drug reimbursement
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
Drug pricing and reimbursement decision making systems in Mongolia
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
Complex pricing and consumer-side transparency
Variables affecting pricing of orphan drugs: the Italian case
Pricing and Reimbursement of Prescription Drugs in German Social Health Insurance
On the welfare analysis of external reference pricing and reimbursement policy
Approval, reimbursement and pricing of high-cost cancer medicines in Australia